URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?



Arimoclomol may reduce the levels of protein aggregates in the motor nerves, a possible cause of ALS, by boosting expression of chaperonins Hsp70 and Hsp90 which help newly synthesized proteins properly fold.


Type: Small Molecule
Stage: Phase II/III
Status: Active
Sponsor: University of Miami

TDI Says:

We do not know if arimoclomol is of benefit to people with ALS. A phase II/III trial is ongoing. However, based on existing pharmacokinetic analyses, we feel more targeted chaperonin inhibitors may prove to be better candidates for ALS therapies.

Published Results

Clinical Trials

Comment on this Topic

(All comments are moderated before they appear here.)